Table 2 Baseline Demographics and Clinical Characteristics
From: Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial
BT (n = 45) | Control (n = 24) | |
|---|---|---|
Age (yrs) | 40.0 ± 11.2 | 40.8 ± 12.1 |
Gender | Male 19 (42%) | Male 9 (38%) |
Female 26 (58%) | Female 15 (63%) | |
Race | White 41 (91%) | White 22 (92%) |
Black 3 (7%) | Black 2 (8%) | |
Asian 1 (2%) | Asian 0 (0%) | |
Height (cm) | 166.1 ± 9.6 | 164.8 ± 7.7 |
Weight (kg) | 76.3 ± 23.3 | 77.7 ± 16.9 |
Inhaled Corticosteroid Dose (μg)a | 1305 ± 880 | 1141 ± 1053 |
LABA Dose (μg)b | 109 ± 34 | 100 ± 15 |
Symptom-Free Days (%) | 33.3 ± 34.3 | 46.1 ± 41.0 |
Asthma Control Questionnaire (ACQ) Score | 1.3 ± 0.6 | 1.2 ± 0.7 |
Asthma Quality of Life Questionnaire (AQLQ) Score | 5.6 ± 0.9 | 5.6 ± 0.9 |
Rescue Medication Use (No. of puffs/7days) | 10.6 ± 14.7 | 5.5 ± 10.4 |
Emergency Room Visits for Respiratory Symptoms in prior 12 months c No. Events (No. Subjects) | 3 (3) | 0 (0) |
Hospitalizations for Respiratory Symptoms in prior 12 months c No. Events (No. Subjects) | 3 (3) | 2 (2) |
Lung Function Measures | ||
Morning PEF (L/min) | 368.4 ± 99.7 | 394.1 ± 111.7 |
Pre-Bronchodilator FEV1 (% predicted) | 72.5 ± 10.9 | 74.9 ± 8.9 |
Post-Bronchodilator FEV1 (% predicted) | 84.4 ± 13.8 | 86.1 ± 9.5 |
Diffusion Capacity (mL/min/mm Hg) | 15.7 ± 10.7 | 15.9 ± 11.7 |
Total Lung Capacity (L) | 6.0 ± 1.2 | 5.9 ± 1.3 |
Residual Volume (L) | 2.1 ± 0.7 | 2.0 ± 0.7 |
Methacholine PC20 (mg/ml) | 0.25 | 0.28 |
Geometric mean (range) | (0.2, 0.4) | (0.1, 0.6) |